Related Experiment Videos
[Thalidomide therapy for discoid lupus erythematosus]
Anna Lyakhovisky1, Sharon Baum, Dorit Shpiro
1Dermatology Department, Sheba Medical Center, Tel Hashomer, Israel. annaly@bezeqint.net
Harefuah
|August 12, 2006
Summary
Low-dose thalidomide effectively treats severe discoid lupus erythematosus (DLE) resistant to other therapies. Most patients achieved remission, though some relapsed after treatment cessation, responding to re-initiation. Side effects were generally mild and transient.
Area of Science:
- Dermatology
- Rheumatology
- Pharmacology
Context:
- Discoid lupus erythematosus (DLE) is a chronic autoimmune skin condition.
- Severe DLE often requires systemic treatment options.
- Thalidomide has shown promise in managing DLE cases.
Purpose:
- To evaluate the efficacy and safety of low-dose thalidomide for disseminated DLE.
- To assess treatment response and adverse effects in patients refractory to other therapies.
Summary:
- Retrospective study of 10 DLE patients treated with 50-200 mg/day thalidomide.
- 90% achieved complete lesion regression within 6 weeks; 40% remained disease-free post-treatment.
- Common side effects included sedation and weight gain; peripheral neuropathy occurred in two patients.
Impact:
- Low-dose thalidomide is a viable treatment for refractory DLE.
- Understanding and managing thalidomide's side effects is crucial for patient safety.
- This study supports thalidomide as an effective option for severe, treatment-resistant DLE.